The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
An Improved Plasmid DNA Expression Vector for Direct Injection into Skeletal Muscle
Abstract
In previous work, the direct injection of 50 μg of a plasmid DNA vector encoding firefly luciferase (VR1205) into murine quadriceps muscle produced an average of 6.5 ng of luciferase per muscle at 7 days postinjection. In this report, various elements of the VR1205 vector were modified to increase gene expression levels or to eliminate undesired viral sequences. Expression of the modified vectors was then compared to VR1205 using the intramuscular injection assay. In general, modifications to promoter, enhancer, and intronic sequences either decreased luciferase expression levels or had no effect. However, modifications to the polyadenylation and transcriptional termination sequences, plasmid backbone elements, and the luciferase gene itself each increased luciferase expression levels. The best-expressing vector, designated VR1255, contained a combination of these incrementally beneficial changes. A single intramuscular injection of 50 μg of VR1255 produced 300 ng of luciferase at 7 days postinjection, an expression level 46-fold higher than the VR1205 vector (or 22-fold higher, excluding modifications to the luciferase gene) and 154-fold higher than a commercially available luciferase expression vector. Thus, VR1255 represents an improved plasmid DNA vector that may be useful for gene therapy applications. The direct injection of plasmid DNA into mouse skeletal muscle was used as an in vivo assay platform to evaluate vector design improvements. Preexisting plasmid DNA vectors were systematically altered and tested, resulting in the production of a new gene therapy vector that can express up to 1 μg of transgene product after a single injection into muscle. The new vector, termed VR1255, represents a significant improvement over previously generated plasmid DNA expression vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Firefly luciferase gene: structure and expression in mammalian cells.
de Wet, J. R., Wood, K. V., DeLuca, M., Helinski, D. R., & Subramani, S. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.2.725 · Cited by 3,087
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J. J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gönczöl, E., & Wilson, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4407 · Cited by 1,575
A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus
BOSHART, M., WEBER, F., JAHN, G., DORSCHHLER, K., FLECKENSTEIN, B., & SCHAFFNER, W. (1985) · Cell · doi:10.1016/s0092-8674(85)80025-8 · Cited by 1,140
A conserved tripeptide sorts proteins to peroxisomes.
Gould, S. J., Keller, G. A., Hosken, N., Wilkinson, J., & Subramani, S. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.5.1657 · Cited by 1,106
Complete nucleotide sequence of SV40 DNA
Fiers, W., Contreras, R., Haegeman, G., Rogiers, R., Van de Voorde, A., Van Heuverswyn, H., Van Herreweghe, J., Volckaert, G., & Ysebaert, M. (1978) · Nature · doi:10.1038/273113a0 · Cited by 1,010
Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs
Acsadi, G., Dickson, G., Love, D. R., Jani, A., Walsh, F. S., Gurusinghe, A., Wolff, J. A., & Davies, K. E. (1991) · Nature · doi:10.1038/352815a0 · Cited by 485
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein.
Sedegah, M., Hedstrom, R., Hobart, P., & Hoffman, S. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9866 · Cited by 447
Self-citationManthorpe, M., Cornefert-Jensen, F., Hartikka, J., Felgner, J., Rundell, A., Margalith, M., & Dwarki, V. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.4-419 · Cited by 432
Self-citation
Cited by
Baumgartner, I., Pieczek, A., Manor, O., Blair, R., Kearney, M., Walsh, K., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.97.12.1114 · Cited by 1,098
DNA vaccines: ready for prime time?
Kutzler, M. A., & Weiner, D. B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2432 · Cited by 1,077
“It remains to be seen whether modifications to the polyadenylation and termination signals influence gene expression, although early reports are promisin”
BackgroundChen, Z.-Y., He, C.-Y., Ehrhardt, A., & Kay, M. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00168-0 · Cited by 462
Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation
Rizzuto, G., Cappelletti, M., Maione, D., Savino, R., Lazzaro, D., Costa, P., Mathiesen, I., Cortese, R., Ciliberto, G., Laufer, R., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6417 · Cited by 325
Isner, J. M. (2002) · Nature · doi:10.1038/415234a · Cited by 309
A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung.
Wheeler, C. J., Felgner, P. L., Tsai, Y. J., Marshall, J., Sukhu, L., Doh, S. G., Hartikka, J., Nietupski, J., Manthorpe, M., Nichols, M., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11454 · Cited by 278
Self-citationThe Inhibitory Effects of Transforming Growth Factor-Beta-1 (TGF-β1) in Autoimmune Diseases
Prud'homme, G. J., & Piccirillo, C. A. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.1999.0339 · Cited by 276
Non-viral and hybrid vectors in human gene therapy: an update
Schmidt-Wolf, G. D., & Schmidt-Wolf, I. G. H. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00005-4 · Cited by 252
Integration-deficient Lentiviral Vectors: A Slow Coming of Age
Wanisch, K., & Yáñez-Muñoz, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.122 · Cited by 222
Modulation of LINE-1 and Alu/SVA Retrotransposition by Aicardi-Goutières Syndrome-Related SAMHD1
Zhao, K., Du, J., Han, X., Goodier, J. L., Li, P., Zhou, X., Wei, W., Evans, S. L., Li, L., Zhang, W., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.019 · Cited by 194
“Moreover, SAMHD1 inhibited ORF2p-mediated Alu and SINE-VNTR-Alu (SVA) retrotransposition activity (Figures S4B–S4E).”
Gene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
Recombinant Adeno-Associated Viral Vectors Mediate Long-Term Transgene Expression in Muscle
Clark, K. R., Sferra, T. J., & Johnson, P. R. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.6-659 · Cited by 153
Advances in Gene Delivery Systems
Kamimura, K., Suda, T., Zhang, G., & Liu, D. (2011) · Pharmaceutical Medicine · doi:10.1007/bf03256872 · Cited by 124
Optimization of Plasmid Vectors for High-Level Expression in Lung Epithelial Cells
Yew, N. S., Wysokenski, D. M., Wang, K. X., Ziegler, R. J., Marshall, J., McNeilly, D., Cherry, M., Osburn, W., & Cheng, S. H. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.5-575 · Cited by 113
LINE1 contributes to autoimmunity through both RIG-I- and MDA5-mediated RNA sensing pathways
Zhao, K., Du, J., Peng, Y., Li, P., Wang, S., Wang, Y., Hou, J., Kang, J., Zheng, W., Hua, S., et al. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.02.007 · Cited by 106
Metadata
- Authors
- Hartikka, J., Sawdey, M., Cornefert-Jensen, F., Margalith, M., Barnhart, K., Nolasco, M., Vahlsing, H. L., Meek, J., Marquet, M., Hobart, P., Norman, J., & Manthorpe, M.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1996-07
- Volume
- 7
- Issue
- 10
- Pages
- 1205-1217
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2031598154
- Cited by
- 328
- References
- 51
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.